window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 24, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Therapeutic Areas

  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Intellia reports first positive Phase 3 in vivo CRISPR data in hereditary angioedema

    Intellia Therapeutics has reported positive Phase 3 results for lonvoguran [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    NETRIS Pharma Nature publishes pancreatic cancer Phase 1b data showing NP137 survival and surgery gains

    Nature publishes Phase 1b data showing NETRIS Pharma’s NP137 improves [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Opinion & Events,Therapeutic Areas

    Abivax to present nine obefazimod studies at DDW as Phase 3 ulcerative colitis data build

    Abivax will present nine scientific abstracts on obefazimod at Digestive [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Alto starts Phase 2b ALTO-207 trial in treatment-resistant depression

    Alto Neuroscience has started a Phase 2b trial of ALTO-207 [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    ARTCLINE completes enrolment in septic shock trial for ARTICE therapy

    ARTCLINE has completed patient enrolment in a 142-patient randomized study [...]

    May 5, 2026
  • Drug Delivery & Formulation,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    ISS National Lab research advances DNA-inspired cancer nanomaterials for chemotherapy and immunotherapy development

    Eascra Biotech is advancing DNA-inspired nanomaterials developed with ISS National [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline

    Neomorph has closed a $100 million Series B financing to [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE expands Lokelma access for hyperkalaemia after draft recommendation

    The National Institute for Health and Care Excellence (NICE) has [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas

    Oncodesign expands ARRONAX deal to secure astatine-211 supply for radiotherapy research

    Oncodesign Services has expanded its collaboration with French research institute [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Regeneron enters radiopharmaceuticals through multi-programme collaboration with Telix in oncology expansion

    Regeneron Pharmaceuticals has entered the radiopharmaceuticals field through a multi-programme [...]

    May 5, 2026
Previous161718Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • FDA grants Fast Track designation to Erasca pancreatic cancer drug
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Anthropic AI protein designs undergo large-scale experimental validation
    Categories: Drug Discovery & Development, Research & Development
  • FDA grants De Novo authorisation to Avulux migraine light-sensitivity lens
    Categories: Clinical & Regulatory, Medical devices, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top